ABUS (Arbutus Biopharma) Quality Rank


ABUS Arbutus Biopharma Corp ABUS
53 GF Score
Price $4.87
GF Value $51.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Arbutus Biopharma Quality Rank Related Terms

ABUS
53GF Score
Arbutus Biopharma Corp ABUS
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arbutus Biopharma (ABUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $4.87 is trading 90.5% below its estimated GF Value™ of $51.20. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for ABUS:

  • Quality Rank:
  • GF Value™: $51.20 vs. price of $4.87 (90.5% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges I9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score

Get the complete analysis for ABUS

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.87
Price
$51.20
GF Value